UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of | (Commission | (I.R.S. Employer |
incorporation or organization) | File Number) | Identification No.) |
(Address of principal executive | ||
offices) | (Zip Code) | |
Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 16, 2026, Accendra Health, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (“NYSE”) Regulation that it has suspended trading of the Company’s common stock and determined to commence proceedings to delist the Company’s common stock from the NYSE. The NYSE Regulation determined that the Company’s common stock is no longer suitable for listing based on abnormally low selling price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual.
The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The Notice states that it will apply to the U.S. Securities and Exchange Commission to delist the Company’s common stock pending completion of applicable procedures, including any appeal by the Company of its determination. The Company does not intend to appeal the NYSE’s determination.
The Company’s common stock began trading on the OTCQB market under the ticker symbol “ACCH” on November 17, 2026.
Item 7.01.Regulation FD Disclosure.
On November 17, 2026, the Company issued a press release regarding the delisting determination. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
The following materials are filed as exhibits to this Current Report on Form 8-K.
Exhibit Number |
| Description |
99.1 | Press Release of the Company, dated November 17, 2026 (furnished pursuant to Item 7.01). | |
104 |
| Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ||||
November 17, 2026 |
| /s/ Jonathan A. Leon | ||
| Jonathan A. Leon | |||
Executive Vice President and Chief Financial Officer | ||||